Drug intelligence / Profile preview

qigui tongfeng

Development stage: Unknown
Lead developer: Lianyungang Kanion
Administration: Oral

Overview

Qigui Tongfeng is a traditional Chinese medicine (TCM) tablet developed by Jiangsu Kanion Pharmaceutical for the treatment of chronic gout. It is specifically formulated to address the 'Qi deficiency and phlegm-dampness obstruction' syndrome, a common TCM classification for chronic gout patients. The drug has undergone Phase 2 clinical evaluation (CTR20160413) to assess its safety and efficacy, as well as to perform dose-finding studies to support the design of subsequent Phase 3 trials. As a botanical product, it likely utilizes a multi-component approach to modulate inflammation and uric acid metabolism.

Brand names: Qigui Tongfeng Granules
Other names: Qigui Tongfeng Tablet芪桂痛风片

Targets

URAT1 (Uric Acid Transporter 1)XO (Xanthine Oxidoreductase)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)

Beyond the preview

Go deeper on qigui tongfeng.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on qigui tongfeng.

Explore the full profile